Pharming Group N.V (PHARM) | Financial Analysis & Statements
Pharming Group N.V. | Mid-cap | Healthcare
Pharming Group N.V. | Mid-cap | Healthcare
Financial Overview
Latest Annual: 2024Income Metrics
Revenue
297.2M
Gross Profit
261.8M
88.09%
Operating Income
-3.7M
-1.23%
Net Income
-11.8M
-3.98%
EPS (Diluted)
-€0.02
Balance Sheet Metrics
Total Assets
400.0M
Total Liabilities
178.9M
Shareholders Equity
221.1M
Debt to Equity
0.81
Cash Flow Metrics
Operating Cash Flow
9.6M
Free Cash Flow
-2.6M
Revenue & Profitability Trend
Pharming Group N.V Income Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 297.2M | 245.3M | 205.6M | 204.2M | 217.9M |
| Cost of Goods Sold | 35.4M | 25.2M | 17.6M | 21.7M | 24.2M |
| Gross Profit | 261.8M | 220.1M | 188.1M | 182.5M | 193.7M |
| Operating Expenses | 256.1M | 233.2M | 171.0M | 156.9M | 114.2M |
| Operating Income | -3.7M | -22.3M | 9.9M | 19.5M | 78.3M |
| Pre-tax Income | -8.5M | -12.0M | 15.0M | 23.7M | 45.3M |
| Income Tax | 3.3M | -1.5M | 1.3M | 7.3M | 6.5M |
| Net Income | -11.8M | -10.5M | 13.7M | 16.4M | 38.8M |
| EPS (Diluted) | -€0.02 | -€0.02 | €0.02 | €0.02 | €0.06 |
Income Statement Trend
Pharming Group N.V Balance Sheet From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | 278.4M | 316.3M | 277.5M | 256.1M | 270.3M |
| Non-Current Assets | 121.5M | 146.5M | 148.3M | 151.8M | 159.4M |
| Total Assets | 400.0M | 462.9M | 425.8M | 408.0M | 429.7M |
| Liabilities | |||||
| Current Liabilities | 73.8M | 78.0M | 59.7M | 48.0M | 78.9M |
| Non-Current Liabilities | 105.1M | 166.1M | 161.5M | 161.9M | 162.4M |
| Total Liabilities | 178.9M | 244.1M | 221.2M | 209.9M | 241.3M |
| Equity | |||||
| Total Shareholders Equity | 221.1M | 218.8M | 204.6M | 198.1M | 188.3M |
Balance Sheet Composition
Pharming Group N.V Cash Flow Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -8.5M | -12.0M | 15.0M | 23.7M | 45.3M |
| Operating Cash Flow | 9.6M | -15.7M | 21.6M | 45.0M | 81.1M |
| Investing Activities | |||||
| Capital Expenditures | - | - | - | - | - |
| Investing Cash Flow | 32.4M | -127.9M | 7.3M | -4.7M | -337.8K |
| Financing Activities | |||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Financing Cash Flow | -34.4M | -5.1M | -1.0M | -24.1M | 64.5M |
| Free Cash Flow | -2.6M | -18.8M | 20.5M | 21.7M | 70.2M |
Cash Flow Trend
Pharming Group N.V Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
57.15
Forward P/E
-92.25
Price to Book
2.88
Price to Sales
1.99
PEG Ratio
-92.25
Profitability Ratios
Profit Margin
-4.40%
Operating Margin
0.96%
Return on Equity
-6.78%
Return on Assets
1.99%
Financial Health
Current Ratio
2.76
Debt to Equity
55.34
Beta
0.54
Per Share Data
EPS (TTM)
-€0.02
Book Value per Share
€0.32
Revenue per Share
€0.48
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| pharm | 637.6M | 57.15 | 2.88 | -6.78% | -4.40% | 55.34 |
| Avantium N.V | 113.2M | -35.65 | 1.17 | -43.03% | -127.72% | 144.79 |
| Vivoryon | 39.2M | -1.85 | 4.97 | -120.41% | 0.00% | 1.29 |
| Aegon | 9.3B | 15.76 | 1.27 | 7.17% | 5.36% | 74.02 |
| Galapagos NV | 1.6B | 51.71 | 0.57 | -6.36% | -58.83% | 0.40 |
| Koninklijke Philips | 18.0B | 74.96 | 1.54 | 1.99% | 2.08% | 64.54 |
Financial data is updated regularly. All figures are in the company's reporting currency.